In a bold move toward a more sustainable future, Daiichi Properties has partnered with Shell Energy Philippines to power its office buildings with renewable energy.

Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a competitive field. Hiroyuki Okuzawa is working to keep it that way.

In a bold move toward a more sustainable future, Daiichi Properties has partnered with Shell Energy Philippines to power its office buildings with renewable energy. The agreement, which took effect ...

Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it failed to prolong the lives of patients in a late-stage study, the ...

Daiichi Sankyo Co. Ltd. and Merck & Co. Inc. have voluntarily pulled the BLA for accelerated approval tied to their HER3-directed antibody-drug conjugate (ADC) in treating EGFR-mutated non-small-cell ...

The IDeate-Esophageal01 study is set to evaluate Merck & Daiichi's ADC drug ifinatamab deruxtecan in pre-treated patients with esophageal squamous cell carcinoma.

Enhertu is currently approved as a second-line treatment for HER2-positive metastatic breast cancer. The new results for the AstraZeneca and Daiichi Sankyo drug in the first-line setting are ...

Following its demutualization and IPO in 2010, Daiichi Life Group has transformed from one of Japan’s big four traditional life insurers to a multinational holding company with a multibrand ...

Daiichi is stepping up its interest in RNA therapies, teaming with Nosis to design drug candidates capable of reaching targets beyond the liver.

Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effe ...

News about Fukushima Daiichi Nuclear Power Plant (Japan). Commentary and archival information about Fukushima Daiichi Nuclear Power Plant (Japan) from The New York Times.